Spectral Medical Future Growth

Future criteria checks 1/6

Spectral Medical is forecast to grow revenue at 14.3% per annum. EPS is expected to grow by 71.8% per annum.

Key information

n/a

Earnings growth rate

71.8%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	14.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	11 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:EDTX.F - Analysts future estimates and past financials data (CAD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	2	N/A	N/A	N/A	1
12/31/2024	2	N/A	N/A	N/A	1
9/30/2024	2	-25	-9	-9	N/A
6/30/2024	2	-19	-9	-9	N/A
3/31/2024	2	-19	-9	-8	N/A
12/31/2023	2	-16	-11	-11	N/A
9/30/2023	2	-10	-11	-11	N/A
6/30/2023	2	-9	-10	-10	N/A
3/31/2023	2	-7	-11	-11	N/A
12/31/2022	2	-8	-10	-10	N/A
9/30/2022	2	-7	-10	-10	N/A
6/30/2022	1	-7	-10	-10	N/A
3/31/2022	2	-7	-10	-9	N/A
12/31/2021	2	-7	-9	-9	N/A
9/30/2021	2	-8	-9	-8	N/A
6/30/2021	2	-8	-9	-8	N/A
3/31/2021	2	-7	-8	-7	N/A
12/31/2020	2	-9	-1	0	N/A
9/30/2020	2	-8	-1	0	N/A
6/30/2020	2	-8	1	1	N/A
3/31/2020	3	-7	2	2	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	4	-3	-2	-2	N/A
6/30/2019	4	-2	-2	-1	N/A
3/31/2019	3	-3	-2	-2	N/A
12/31/2018	4	-2	-2	-2	N/A
9/30/2018	3	-4	-3	-3	N/A
6/30/2018	3	-4	N/A	-3	N/A
3/31/2018	4	-4	N/A	-3	N/A
12/31/2017	4	-4	N/A	-4	N/A
9/30/2017	4	-4	N/A	-5	N/A
6/30/2017	4	-6	N/A	-7	N/A
3/31/2017	3	-8	N/A	-9	N/A
12/31/2016	4	-10	N/A	-11	N/A
9/30/2016	3	-11	N/A	-11	N/A
6/30/2016	3	-11	N/A	-10	N/A
3/31/2016	3	-10	N/A	-9	N/A
12/31/2015	3	-10	N/A	-9	N/A
9/30/2015	3	-10	N/A	-9	N/A
6/30/2015	3	-9	N/A	-9	N/A
3/31/2015	3	-9	N/A	-9	N/A
12/31/2014	3	-9	N/A	-10	N/A
9/30/2014	3	-11	N/A	-11	N/A
6/30/2014	3	-12	N/A	-10	N/A
3/31/2014	3	-12	N/A	-10	N/A
12/31/2013	3	-11	N/A	-9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EDTX.F's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if EDTX.F's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if EDTX.F's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EDTX.F's revenue (14.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: EDTX.F's revenue (14.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EDTX.F's Return on Equity is forecast to be high in 3 years time

Spectral Medical Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

Spectral Medical Inc. Provides October Tigris Trial Update

Spectral Medical Inc. Provides September Tigris Trial Update

Spectral Medical Inc. Provides August Tigris Trial Update

Spectral Medical Inc Provides July Tigris Trial Update

Spectral Medical Inc. announced that it has received $1 million in funding

Spectral Medical Inc. announced that it expects to receive $1 million in funding

Spectral Medical Inc. Provides June Tigris Trial Update

Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding

Spectral Medical Inc. Provides Tigris Trial Update

Spectral Medical Provides Tigris Trial Update

Spectral Medical Inc. Announces Board Changes

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Spectral Medical Provides Tigris Trial Update

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

Spectral Medical Inc., Annual General Meeting, Jun 03, 2021

Spectral Medical Inc. Announces Chief Executive Officer Changes, Effective April 1, 2021

Spectral Medical Inc Crescendo Communications to Provide Investor Relations Services in the United States

Spectral Medical Announces That Its Wholly-Owned Subsidiary Dialco Medical Has Been Granted FDA IDE Authorization to Conduct Trial of Dimi for Home Hemodialysis Use

Spectral Medical Inc Appoints John Kellum as Chief Medical Officer Effective March 1, 2021

Spectral Medical Inc. Announces its Wholly Owned Subsidiary Dialco Medical Receives Mdsap Certification

Spectral Medical Announces Report on Clinical Implementation of Sami Amid Covid-19 Published in the Journal of Blood Purification

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies